Novo Nordisk's Main Europe Problem Is Reimbursement

REPLAY VIDEO
Your next video will start in
Pause
  • Info

  • Comments

May 1 (Bloomberg) -- Jesper Brandgaard, chief financial officer of Novo Nordisk A/S, discusses its Tresiba diabetes treatment, European Medicines Agency concerns about its diabetes treatment Victoza and challenges in the European market. He speaks from Copenhagen with Francine Lacqua and Caroline Hyde on Bloomberg Television's "On the Move." (Source: Bloomberg)

Advertisement

BTV Channel Finder

Channel_finder_loader

ZIP is required for U.S. locations

Bloomberg Television in   change